Lovastatin Tablet
Product Images NDC 51655-686

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 51655-686). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 686 52 Master Bottle Label Approval Rev A 04 21)

Label for Lovastatin Tablets USP 10 mg oral tablets, packaged in a 30-tablet quantity. The label includes storage instructions to keep the product at controlled room temperature (20°-25°C) and to protect from light. The product is labeled as prescription only and repackaged by Northwind Pharmaceuticals for Northwind Health Company, LLC.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of Lovastatin, showing its molecular configuration with functional groups and stereochemistry details, consistent with the active ingredient Lovastatin in a prescription oral tablet form.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' showing drug names, number of subjects, dosing of coadministered drug or grapefruit juice, dosing of Lovastatin, and AUC ratio comparisons with and without coadministered drugs. The table lists drugs like Gemfibrozil, Itraconazole, Grapefruit Juice, Cyclosporine, and Diltiazem with corresponding dosing details and AUC ratio effects on Lovastatin exposure.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' comparing the proportion of participants without events over six years of follow-up between Lovastatin and placebo groups. The Lovastatin group shows a higher proportion without events and a noted 37% risk reduction compared to the placebo group, with statistical significance (p<0.001).*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' outlining interacting agents and prescribing recommendations for lovastatin. It lists strong CYP3A4 inhibitors, HIV protease inhibitors, and other drugs with advisories such as contraindications, dose limits, and avoidance of grapefruit juice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.